President and CEO, Anaphore Inc.
CEO, CyPhy Works
Co-Founder and CEO, Seattle Genetics
Lecturer in Innovation and Entrepreneurship, MIT
Dir., Alzheimer's Disease Research Inst., Cornell Medical College
Co-Founder, Sakti3
Partner, Emerging Companies and Life Sciences, Cooley LLP
|
|
What are the most powerful forces affecting innovation and the economy? That is one of the key questions facing the nation as we inch our way out of the economic mire.
Juan Enriquez may not have all the answers, but he... Read more »
Karyopharm Therapeutics believes it can build a platform of cancer drugs off of the idea of keeping the body’s tumor-suppressing proteins in the nucleus of cells, where they can do their jobs properly. With the help of a new $48.2 million... Read more »
NanoString Technologies just started selling its first diagnostic test after 10 years in business, and now it’s getting ready for another milestone—an initial public offering.
The Seattle-based company said today that it is seeking to raise as much as $86.3 million... Read more »
When Astellas Pharma shuttered the labs of OSI Pharmaceuticals last week, no one felt that loss as acutely as the residents of Long Island, NY. OSI, famed for its lung cancer drug erlotinib (Tarceva), had shown that it was possible to... Read more »
Biotech industry conferences are happening, somewhere on this green Earth, every day. If you’ve been around a while, and you’ve attended a few, chances are you get invitations, or marketing pitches, that ask you to attend a different meeting every day.... Read more »
Few could accuse XBiotech CEO John Simard of failing to think big.
The Austin, TX-based startup he founded in 2005 is testing a novel biological drug candidate that is aiming to treat the persistent inflammation that makes cancer patients feel so... Read more »
[Clarification 5/17/13, 2:05 pm. See below.] Right on the same line with the original lede so you don’t waste space on a carriage return…Antibody drugs seemed to be the topic of the week for San Diego’s life sciences community.... Read more »
All eyes in the biotech world will soon turn to the American Society of Clinical Oncology’s annual meeting in Chicago, but for now, the industry keeps humming along. This week’s news was highlighted by partnerships, product launches and big name hirings—and... Read more »
Science news often falls into the trap of becoming “infotainment” designed to generate ratings, and little else. As one essayist in The Guardian recently put it, “freaky copulation techniques in the animal kingdom,” heart-warming tales of miracle cures for kids, or... Read more »
AnaptysBio says today the U.S. government has asked the San Diego biotech to produce antibodies that counter the deadly effects of ricin and would not require refrigeration, so batches of anti-ricin antibodies could be stored at room temperatures.
Under a contract... Read more »
San Diego’s Ambit Biosciences cut the share price of its planned IPO by nearly half yesterday, but still managed to raise about $65 million by increasing the number of shares in its debut offering. Shares of the biopharmaceutical company began trading... Read more »
Matrix Genetics is one of those startups that never really got off the ground in its early days, but never died, either. While the Seattle-based company lived on fumes at various points over the past four years, it saw other contenders... Read more »
Less than a decade after being hatched out of a Texas university, Houston-based Bellicum Pharmaceuticals is in the midst of clinical trials on two innovative cancer therapies that, if successful, could result in new ways of attacking and killing off harmful... Read more »
It’s been almost two years since Paul Grayson was named as CEO of San Diego’s Anaphore—more than enough time for the former Fate Therapeutics CEO to put a new strategy in place.
The company unveiled the first element of its new... Read more »
[Corrected on 5/16/13, 9:11 a.m., see below] Fresh off raising $265 million to bankroll its ninth fund, Atlas Venture has forged strategic partnerships with Amgen and Novartis to help supply the bigger companies with innovative new drug candidates. The... Read more »
Genentech made its name in cancer by creating targeted antibody drugs that zero in on tumor cells while mostly sparing healthy tissue. Now it’s seeking to compete in the next wave of cancer immunotherapies, which are designed to spark the immune... Read more »
Genentech has been searching for years to find a way to improve upon rituximab (Rituxan), which set a gold standard 15 years ago as part of the first generation of targeted antibody cancer drugs. Now it looks like Genentech... Read more »
Gradalis today revealed early details of a study indicating that its personalized cancer vaccine could delay recurrences of ovarian cancer in advanced stage patients by at least a year.
The Dallas-based startup, founded in 2005, presented results of a phase II... Read more »
OSI Pharmaceuticals became the home-grown beacon of Long Island, NY’s biotech scene behind the lung cancer drug erlotinib (Tarceva), which was so successful that led Japan’s Astellas Pharma to buy the company outright in a $4 billion deal in May 2010.... Read more »
Dean of the University of Colorado Law School
Professor of Bioengineering, Stanford University
Director, Neurobiotics Laboratory, University of Washington
Founder and CEO, BzzAgent
Dean, Harvard School of Engineering and Applied Sciences
San Francisco · 6/3/13
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
